SHORT MINI-FUTURE - GENMAB | Real-time Bid/Ask 06:21:03 2024-07-17 am EDT | ||
| 25.01 EUR / 25.03 EUR | +1.38% |
|
| Current month | -1.28% | ||
| 1 month | +0.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 24.48 | -0.81% |
| 24-07-16 | 24.68 | +3.09% |
| 24-07-15 | 23.94 | -3.23% |
| 24-07-12 | 24.74 | -2.48% |
| 24-07-11 | 25.37 | +0.32% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 02:28 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VQ97WT |
| ISIN | DE000VQ97WT7 |
| Date issued | 2021-08-04 |
| Strike | 3,676 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 14.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.42 € |
|---|---|
| Lowest since issue | 5.03 € |
| Spread | 0.02 € |
| Spread % | 0.08% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,828
DKK
Average target price
2,446
DKK
Spread / Average Target
+33.83%
- Stock Market
- Certificates
- Certificat
